Over the past few years, other trials have focused on other melanoma markers, such as the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and melanoma antigen family A3 (MAGE-A3), obtaining encouraging results in terms of survival. This evidence concerns the gene MAGEA3 and melanoma.